CompanDX

The collaboration draws on ResearchDx's ability to design, produce, and validate tests, and CompanDx's Distiller platform to deliver small composite biomarker signatures from complex data of high dimensionality.

Under the terms of the multi-year agreement, the partners will advance diagnostic tests, from biomarker discovery to test validation, applying CompanDx's Risk Distiller bioinformatics tool and CRL's CLIA-certified laboratory services.

The partners said they will collaborate on the development of biomarker panels and companion diagnostics for pharmaceutical, biotech, and academic clients worldwide.

The 31-gene signature, used to predict the time to cancer metastasis after initial surgery and biopsy, has been validated by CompanDX researchers in four different datasets, according to the company.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.